
- /
- Supported exchanges
- / US
- / VTYX.NASDAQ
Ventyx Biosciences Inc (VTYX NASDAQ) stock market data APIs
Ventyx Biosciences Inc Financial Data Overview
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ventyx Biosciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ventyx Biosciences Inc data using free add-ons & libraries
Get Ventyx Biosciences Inc Fundamental Data
Ventyx Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -130 108 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ventyx Biosciences Inc News

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral t...


Ventyx (VTYX) Q2 Net Loss Drops 16%
Key Points EPS (GAAP) of $0.38 for Q2 2025 exceeded the analyst estimate of $(0.47), Research and development and general administrative expenses (GAAP) decreased year over year. This decrease result...

Top Penny Stocks To Watch In July 2025
Over the last 7 days, the United States market has risen 1.4%, contributing to a 17% climb over the past year, with future earnings expected to grow by 15% annually. Penny stocks may be a throwback te...

Sight Sciences Leads The Pack Of 3 Promising Penny Stocks
The United States market has remained flat over the past week but is up 11% over the past year, with earnings projected to grow by 15% annually. Though the term 'penny stock' might sound like a relic ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.